Get the Straight DOPE - Issue #1
Welcome to DOPE, the Department Of Peptide Ethics, a Finnrick.com newsletter, where we’re on a mission to make sovereign health safer, one vial at a time.
After analyzing hundreds of peptide samples and watching enough HPLC peaks to make our eyes cross, we've got some hard data you need to see. No marketing fluff, no bro-science—just chromatography doesn't lie.
The Good, The Bad, The Regrettable
Polaris and Skye Peptides: The Consistency Kings
Polaris has emerged as one of the most reliable vendors in our testing. They've earned A ratings for their Tirzepatide and Semaglutide, but also Retatrutide which seems challenging for several other vendors.
Another standout is Skye Peptides, earning A ratings across Semaglutide, Tirzepatide, and Retatrutide. See more Skye test results →
The Jekyll & Hyde Award to be shared by Forever Young Pharmacy and Peptide Sciences
Talk about split personality! Forever Young Pharmacy scores an A for Semaglutide but an E for Retatrutide. Why the dramatic difference? Their "Retatrutide" failed identity tests across multiple labs - could be mislabeled Tirzepatide, or something else entirely. Not great.
Similarly, Peptide Sciences earns an E rating for their Retatrutide, probably mislabeled Tirzepatide. All the more disappointing that their BPC-157 scores an A. Check out all Peptide Sciences product ratings →
Quantity Shenanigans: The Overfill Champions
Several vendors are significantly overfilling their vials:
- NextechLabs Tirzepatide labeled as 10mg actually contained 37.5mg (275% more! Looks like mislabeling.)
- Peptide Crafters Semaglutide 5mg vials contained 11.3mg (127% more – that seems more like being too generous.)
Sounds like free product, but when it comes to peptides, precision dosing matters, and we'd certainly prefer to see more accurate quality assurance.
📰 Sovereign Health News
- BPC-157’s FDA Dreams Dashed? X activist doc @abudbakri breaks down why this healing peptide will probably never get the FDA nod despite clinical buzz.
- Semaglutide: Beyond Diabetes. The Wall Street Journal joins in on the excitement about Semaglutide’s anti-aging potential—Ozempic’s not just for blood sugar anymore.
- FDA Tightens the Reins. Post-court ruling, the FDA confirms no more compounding exemptions for Semaglutide as supply stabilizes, people are talking about stockpiling.
- Oprah Weighs In. On her podcast, Oprah mentioned the DIY peptide trend—skeptical, but she’s listening.
- Eli Lilly’s Oscar Jab. Their ad during the Oscars took a swing at alternative therapies—Big Pharma’s not happy.
Have a Peptide You Want Tested?
Our testing program continues to expand. If you have a peptide product you'd like us to analyze, or a vendor you're curious about, let us know.